Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01295944 · ClinicalTrials.gov registry record · Phase 2
Carboplatin and Bevacizumab for Recurrent Ependymoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01295944: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01295944 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01295944, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if the combination of bevacizumab and carboplatin can help to control recurrent ependymoma. The safety of this drug combination will also be studied.
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-04-27 |
| Est. Completion | 2021-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01295944
The ClinicalTrials.gov registry entry for NCT01295944 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT01295944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01295944 about?
NCT01295944 is a clinical study titled "Carboplatin and Bevacizumab for Recurrent Ependymoma". The goal of this clinical research study is to learn if the combination of bevacizumab and carboplatin can help to control recurrent ependymoma. The safety of this drug combination will also be studied.
What is the current status of trial NCT01295944?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2011-04-27. Estimated completion is 2021-05-14.
What interventions are being tested in trial NCT01295944?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG).
Who is sponsoring clinical trial NCT01295944?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.